| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | Ioannis E. Koutroubakis | Q39900304 |
| P2860 | cites work | Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee | Q22242348 |
| Probiotics for induction of remission in ulcerative colitis | Q24242963 | ||
| Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis | Q24243219 | ||
| Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine | Q24685766 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences | Q29617565 | ||
| Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. | Q30581062 | ||
| Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis | Q33912325 | ||
| European evidence-based Consensus on the management of ulcerative colitis: Current management | Q34025054 | ||
| Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study | Q34100121 | ||
| Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up | Q80793210 | ||
| Oral methotrexate in ulcerative colitis | Q81399575 | ||
| Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis | Q84852617 | ||
| Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations | Q34396521 | ||
| A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis | Q34409303 | ||
| Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. | Q34606666 | ||
| Restorative proctocolectomy for distal ulcerative colitis | Q35357383 | ||
| Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial | Q35719665 | ||
| Optimizing management of distal ulcerative colitis | Q36459902 | ||
| Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement | Q36609204 | ||
| Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis | Q37011986 | ||
| Therapy of ulcerative colitis: state of the art. | Q37214370 | ||
| Strategies to improve adherence and outcomes in patients with ulcerative colitis | Q37354123 | ||
| Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis | Q37458969 | ||
| Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine | Q37529888 | ||
| A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis | Q39453095 | ||
| Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology | Q40390478 | ||
| A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis | Q41735945 | ||
| Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis | Q42788696 | ||
| Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis | Q43286532 | ||
| Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. | Q43292530 | ||
| Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis | Q43566966 | ||
| Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis | Q43788265 | ||
| Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. | Q44006203 | ||
| Gastrointestinal transit and release of 5‐aminosalicylic acid from 153Sm‐labelled mesalazine pellets vs. tablets in male healthy volunteers | Q44444418 | ||
| Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. | Q44488900 | ||
| Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis | Q44643593 | ||
| Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial | Q45192026 | ||
| Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis | Q46400709 | ||
| A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. | Q46469247 | ||
| Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
| Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. | Q46605939 | ||
| Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial | Q46798247 | ||
| Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. | Q51872306 | ||
| Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. | Q55042707 | ||
| Epidemiology of Clostridium difficile Colitis in Hospitalized Patients with Inflammatory Bowel Diseases | Q58877733 | ||
| VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis | Q59120549 | ||
| Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal | Q61657104 | ||
| Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial | Q71035874 | ||
| Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment | Q73204666 | ||
| Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group | Q77164841 | ||
| Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis | Q79596195 | ||
| Once-daily, high-concentration MMX mesalamine in active ulcerative colitis | Q79621238 | ||
| Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study | Q79905651 | ||
| Azathioprine dose escalation in inflammatory bowel disease | Q80260043 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 43-50 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | World journal of gastrointestinal pharmacology and therapeutics | Q27723537 |
| P1476 | title | Recent advances in the management of distal ulcerative colitis | |
| P478 | volume | 1 |
| Q35953205 | Autophagy Protects against Colitis by the Maintenance of Normal Gut Microflora and Secretion of Mucus |
| Q36775698 | Differential DNA methylation patterns of homeobox genes in proximal and distal colon epithelial cells. |
| Q36405121 | Glutamine supplementation attenuates ethanol-induced disruption of apical junctional complexes in colonic epithelium and ameliorates gut barrier dysfunction and fatty liver in mice. |
Search more.